Protalix BioTherapeutics, Inc. SEC filings PLX
Protalix BioTherapeutics, Inc. has 972 filings in SEC EDGAR's recent list, going back to Aug 13, 1996. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 12, 2026 | — |
| 424B5 | Prospectus supplement | Aug 22, 2025 | — |
| S-3/A | Filing | Aug 14, 2025 | — |
| S-3 | Shelf registration | Apr 28, 2025 | — |
| 424B5 | Prospectus supplement | Mar 17, 2025 | — |
| S-8 | Employee stock plan registration | Jul 1, 2024 | — |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 424B3 | Prospectus | Jul 7, 2023 | — |
| 424B5 | Prospectus supplement | Feb 27, 2023 | — |
| S-8 | Employee stock plan registration | Jul 14, 2022 | — |
| 424B5 | Prospectus supplement | May 2, 2022 | — |
| S-3 | Shelf registration | Apr 20, 2022 | — |
| 424B5 | Prospectus supplement | Jul 2, 2021 | — |
| 424B5 | Prospectus supplement | Jul 2, 2021 | — |
| 424B5 | Prospectus supplement | Feb 16, 2021 | — |
| 424B5 | Prospectus supplement | Feb 11, 2021 | — |
| 424B5 | Prospectus supplement | Oct 1, 2020 | — |
| S-8 | Employee stock plan registration | Jun 11, 2020 | — |
| 424B3 | Prospectus | Apr 29, 2020 | — |
| S-3 | Shelf registration | Apr 17, 2020 | — |
| S-3 | Shelf registration | Mar 29, 2019 | — |
| S-8 | Employee stock plan registration | Jun 8, 2018 | — |
| S-3/A | Filing | Nov 27, 2015 | — |
| S-3 | Shelf registration | Nov 13, 2015 | — |
| S-8 | Employee stock plan registration | May 7, 2015 | — |
| S-8 | Employee stock plan registration | Jul 16, 2012 | — |
| 424B5 | Prospectus supplement | Feb 16, 2012 | — |
| 424B5 | Prospectus supplement | Feb 15, 2012 | — |
| 424B5 | Prospectus supplement | Mar 18, 2011 | — |
| 424B5 | Prospectus supplement | Mar 17, 2011 | — |
| S-3 | Shelf registration | Jan 10, 2011 | — |
| POS AM | Pos am: post-effective amendment no. 1 to form s-3 | Dec 19, 2008 | — |
| POS AM | Filing | Dec 19, 2008 | — |
| S-8 | Employee stock plan registration | Feb 1, 2008 | — |
| 424B5 | Prospectus supplement | Oct 25, 2007 | — |
| S-3MEF | Form s-3mef | Oct 25, 2007 | — |
| 424B5 | Prospectus supplement | Oct 5, 2007 | — |
| S-3/A | Amendment no. 2 to form s-3 | Sep 24, 2007 | — |
| S-3/A | Amendment no. 1 to form s-3 | Sep 24, 2007 | — |
| S-3 | Shelf registration | Jul 24, 2007 | — |
| 424B3 | Prospectus | Mar 30, 1998 | — |
| S-4 | Registration for a merger or exchange | Mar 26, 1998 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PLX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hackensack, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006281
- Former names
- ORTHODONTIX INC (until Feb 22, 2007); EMBASSY ACQUISITION CORP (until Mar 31, 1998)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.